Canaccord Genuity Maintains Buy on Artivion, Raises Price Target to $40
Canaccord Genuity analyst William Plovanic maintains Artivion (NYSE:AORT) with a Buy and raises the price target from $39 to $40.
Stocks · News reference
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval
Artivion secured FDA PMA approval for AMDS, removing IRB hurdles and expanding access for acute aortic dissection patients.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est
Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.
Artivion Q2 Adj. EPS $0.13 Beats $0.01 Estimate, Sales $125.757M Beat $120.012M Estimate
Needham Reiterates Buy on Artivion, Maintains $44 Price Target
Needham analyst Mike Matson reiterates Artivion (NYSE:AORT) with a Buy and maintains $44 price target.